Fate Therapeutics (FATE) Operating Leases (2019 - 2026)

Fate Therapeutics has reported Operating Leases for 8 years, with the latest figure at $72.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 6.17% year-over-year to $72.0 million; the trailing twelve-month figure through Mar 2026 stood at $72.0 million (down 6.17% YoY), and the FY2025 full-year result was $73.3 million, down 5.86% from the prior year.
• Operating Leases for Q1 2026 stood at $72.0 million, down from $73.3 million in the prior quarter.
• The five-year high for Operating Leases was $107.9 million in Q1 2022, with the low at $72.0 million in Q1 2026.
• Historically, Operating Leases has averaged $91.4 million across 5 years, with a median of $95.7 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases climbed 1.34% — and 2024, when it dropped 20.04%.
• Fate Therapeutics' Operating Leases stood at $103.7 million in 2022, then decreased by 6.12% to $97.4 million in 2023, then retreated by 20.04% to $77.8 million in 2024, then decreased by 5.86% to $73.3 million in 2025, then fell by 1.69% to $72.0 million in 2026.
• The last three Operating Leases figures came in at $72.0 million (Q1 2026), $73.3 million (Q4 2025), and $74.5 million (Q3 2025), per Business Quant data.